Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL201 with toripalimab with or without platinum chemotherapy in recurrent or metastatic nasopharyngeal carcinoma
CTR20254191Phase 2Active
- Sponsor
- MediLink Therapeutics
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of YL201 in nasopharyngeal carcinoma (NPC), sponsored by MediLink Therapeutics. Started Nov 2025; status: active.
02
Drugs
YL201
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20254191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254191.